Results 31 to 40 of about 2,368 (193)

Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season

Vaccines
Respiratory syncytial virus (RSV) bronchiolitis remains a significant global health burden, particularly in newborns and infants during their first year of life.
Alessandra Consolati, Mariapaola Farinelli, Paolo Serravalle, Christine Rollandin, Laura Apprato, Susanna Esposito, Salvatore Bongiorno   +6 more
doaj   +3 more sources

Long-acting monoclonal antibodies and the evolving landscape of infant respiratory syncytial virus prevention. [PDF]

Pediatr Investig
Pediatric Investigation, Volume 10, Issue 4, Page 293-299, August 2026.
Wang R, Abu-Raya B, Obeid H, Xie Z.
europepmc   +2 more sources

Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria [PDF]

Frontiers in Public Health
BackgroundSince summer 2024, passive immunization with nirsevimab (Beyfortus®) has been recommended for all infants in Austria to prevent severe respiratory syncytial virus (RSV) infection.
Michaela Höck, Wegene Borena, Jürgen Brunner, Karina Wechselberger, Johanna Scheiring, Elisabeth Ralser, Ulrike Pupp Peglow, Peter Wöckinger, Elisabeth D’Costa, Verena Kaiser, Klaus Kapelari, Gisa Gerold, Thomas Müller, Ursula Kiechl-Kohlendorfer, Elke Griesmaier   +14 more
doaj   +2 more sources

Postpandemic Trends in Pediatric Respiratory Virus Hospitalizations: A Multicenter Study, 2019-2025. [PDF]

Influenza Other Respir Viruses
ABSTRACT Background The COVID‐19 pandemic profoundly altered the circulation of respiratory viruses in children, changing the epidemiology of acute lower respiratory tract infections. In the postpandemic period, respiratory pathogens showed marked temporal variability. The 2024–2025 season was the first respiratory syncytial virus (RSV) season in Italy
Attaianese F, Campani S, Trapani S, Alberti I, Aricò M, Attanasi M, Bertolucci G, Bressan S, Caselli D, Casotto V, Cazzato S, Chiarelli F, Felici E, Frusciante A, Galeone MA, Garazzino S, Giannattasio A, Gitto E, Guerriero A, Guida F, Iudica G, Lanari M, Mandato C, Manzini A, Martelli G, Milani GP, Moriondo M, Notarangelo LD, Nunziata F, Pellegrino R, Peroni D, Piccotti E, Ponticiello E, Ricci S, Rulli I, Savoia F, Silvestro E, Sisto A, Soro F, Tonetto S, Zago A, Dani C, Azzari C, Indolfi G.   +43 more
europepmc   +2 more sources

Comparative Analysis of Reported Adverse Events with Nirsevimab and Palivizumab in the FAERS Database. [PDF]

Kans J Med
Introduction. Respiratory syncytial virus (RSV) remains a leading cause of hospitalization among infants. Palivizumab has long been used for RSV prophylaxis in high-risk infants, whereas nirsevimab is a newer long-acting monoclonal antibody approved for ...
Touffaha I, Ablah E, Okut H, Homan G.
europepmc   +2 more sources

Sociodemographic and Clinical Factors Associated With Nirsevimab Receipt Among Children Aged Younger Than 20 Months in the New Vaccine Surveillance Network in 2023 to 2025. [PDF]

Hosp Pediatr
OBJECTIVES We aim to evaluate the association of sociodemographic and clinical factors with nirsevimab receipt among children with medically attended acute respiratory illness (ARI) across multiple seasons and ...
Teoh Z, Tannis A, Sullivan E, Boom JA, Halasa N, Michaels MG, Payne DC, Sahni LC, Schuster J, Selvarangan R, Staat MA, Stewart LS, Szilagyi PG, Weinberg GA, Williams JV, Dawood FS, Klein EJ, Moline H, Englund JA, Zerr DM.   +19 more
europepmc   +2 more sources

Recommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children [PDF]

Clinical and Experimental Pediatrics
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections (LRTIs) in infants and young children. In April 2024, the Korea Ministry of Food and Drug Safety approved nirsevimab (Beyfortus), a long-acting monoclonal ...
Soo-Han Choi, Dong Hyun Kim, Jong Gyun Ahn, Ki Wook Yun, Byung-Wook Eun, Jin Lee, Jina Lee, Taek-Jin Lee, Hyunju Lee, Dae Sun Jo, Eun Young Cho, Hye-Kyung Cho, Young June Choe, Ui Yoon Choi, Yun-Kyung Kim, The Committee on Infectious Diseases of the Korean Pediatric Society   +15 more
doaj   +1 more source

Evaluation of nirsevimab against rsv infection in infants

, 2023
19 p.ill.,LIST OF TABLES 1 -- BACKGROUND 3 -- 1 BACKGROUND 4 -- 2 METHODS 4 -- 3 CLINICAL EVIDENCE 7 -- 3.1 NIRSEVIMAB IN PRETERM INFANTS 7 -- 3.2 NIRSEVIMAB IN LATE-PRETERM AND TERM INFANTS 9 -- 3.3 MEDLEY TRIAL 14 -- 3.4 HARMONIE TRIAL (PRELIMINARY ...
Desimpel, Fabian
core   +1 more source

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection

Frontiers in Immunology, 2023
IntroductionNirsevimab is an extended half-life (M252Y/S254T/T256E [YTE]-modified) monoclonal antibody to the pre-fusion conformation of the respiratory syncytial virus (RSV) Fusion protein, with established efficacy in preventing RSV-associated lower ...
Tyler Brady, Corinne Cayatte, Tiffany L. Roe, Scott D. Speer, Hong Ji, LeeAnn Machiesky, Tianhui Zhang, Deidre Wilkins, Kevin M. Tuffy, Elizabeth J. Kelly   +9 more
doaj   +1 more source

The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis

Frontiers in Pediatrics, 2023
BackgroundRespiratory syncytial virus (RSV) is a leading cause of morbidity and mortality among infants with a global incidence of 9.5% and a mortality rate of 2.2%. The management of RSV infection is mainly supportive and, aside from emerging monoclonal
Maria Wilma R. Turalde-Mapili, Jerahmeel Aleson L. Mapili, Christian Wilson R. Turalde, Christian Wilson R. Turalde, Marimel R. Pagcatipunan   +4 more
doaj   +1 more source